POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Emicizumab (Primary) ; Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms POCUS
- 27 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jul 2025.
- 27 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2025.
- 21 Apr 2021 Status changed from not yet recruiting to recruiting.